Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines

BACKGROUND: Studies in taxane and/or anthracycline refractory metastatic breast cancer (mBC) patients have shown approximately 30 % response rates to irinotecan. Hence, a significant number of patients will experience irinotecan-induced side effects without obtaining any benefit. The aim of this stu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Jandu, Haatisha, Aluzaite, Kristina, Fogh, Louise, Thrane, Sebastian Wingaard, Noer, Julie B., Proszek, Joanna, Do, Khoa Nguyen, Hansen, Stine Ninel, Damsgaard, Britt, Nielsen, Signe Lykke, Stougaard, Magnus, Knudsen, Birgitta R., Moreira, José, Hamerlik, Petra, Gajjar, Madhavsai, Smid, Marcel, Martens, John, Foekens, John, Pommier, Yves, Brünner, Nils, Schrohl, Anne-Sofie, Stenvang, Jan
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4722663/
https://ncbi.nlm.nih.gov/pubmed/26801902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2071-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados